Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Down 5 7% in March theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Aldeyra Therapeutics, Inc. , a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the clinical.
Aldeyra Therapeutics, Inc. announced the clinical development plan intended to enable resubmission of a New Drug Application of topical ocular 0.25% reproxalap, an investigational RASP modulator, for.
Aldeyra Therapeutics, Inc (NASDAQ:ALDX – Get Free Report) insider Bruce Greenberg sold 13,201 shares of Aldeyra Therapeutics stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $3.41, for a total transaction of $45,015.41. Following the sale, the insider now directly owns 120,699 shares in the […]